CSL (OTCMKTS:CSLLY) Stock Rating Upgraded by Canaccord Genuity Group

CSL (OTCMKTS:CSLLY) was upgraded by analysts at Canaccord Genuity Group from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Separately, Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Monday, October 20th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy”.

CSL Stock Down 4.5%

CSLLY stock opened at $55.99 on Tuesday. The company’s 50 day moving average price is $67.94 and its 200 day moving average price is $76.20. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.12 and a current ratio of 2.46. CSL has a fifty-two week low of $54.10 and a fifty-two week high of $97.09.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.